Vir Biotechnology Files Proxy Statement for 2024 Annual Meeting

TL;DR

Vir Bio's proxy statement is out for the May 29th meeting - vote on directors & auditors.

AI Summary

Vir Biotechnology, Inc. filed its definitive proxy statement on April 19, 2024, for its annual meeting of stockholders scheduled for May 29, 2024. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items include the election of directors and the ratification of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024.

Why It Matters

This filing provides shareholders with crucial information regarding the company's leadership, compensation practices, and key decisions to be made at the upcoming annual meeting, impacting their investment and the company's future direction.

Risk Assessment

Risk Level: low — This is a routine annual filing (DEF 14A) that provides information to shareholders and does not contain new material events or financial disclosures that would inherently increase risk.

Key Numbers

• 2024 — Fiscal Year End (The company's fiscal year ends on December 31st, as stated in the filing.)

Key Players & Entities

• Vir Biotechnology, Inc. (company) — Registrant
• May 29, 2024 (date) — Annual Meeting Date
• April 19, 2024 (date) — Filing Date
• PricewaterhouseCoopers LLP (company) — Independent Registered Public Accounting Firm

FAQ

From the Filing

0001140361-24-020684.txt : 20240419 0001140361-24-020684.hdr.sgml : 20240419 20240419083238 ACCESSION NUMBER: 0001140361-24-020684 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 21 CONFORMED PERIOD OF REPORT: 20240529 FILED AS OF DATE: 20240419 DATE AS OF CHANGE: 20240419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 24855696 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 DEF 14A 1 edge20022607x1_def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ ​ ​ Filed by a Party other than the Registrant   ☐ Check the appropriate box:   ☐ Preliminary Proxy Statement   ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement   ☐ Definitive Additional Materials   ☐ Soliciting Material Pursuant to §240.14a-12 Vir Biotechnology, Inc. (Name of Registrant as Specified In Its Charter)   (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ ​ ​ No fee required   ☐ ​ ​ Fee paid previously with preliminary materials   ☐ ​ ​ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. TABLE OF CONTENTS VIR BIOTECHNOLOGY, INC.   1800 Owens Street, Suite 900 San Francisco, California 94158 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS   To Be Held On May 29, 2024 Dear Stockholder: On behalf of the Board of Directors, you are cordially invited to attend the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of Vir Biotechnology, Inc., a Delaware corporation (the “Company”). The Annual Meeting will be held on Wednesday, May 29, 2024, at 9:00 a.m. Pacific Time. You can attend the Annual Meeting by visiting www.virtualshareholdermeeting.com/VIR2024 where you will be able to listen to the meeting live, submit questions and vote online. You will need the 16-digit control number included on your Notice of Internet Availability of Proxy Materials or proxy card to attend the Annual Meeting virtually. We are holding the Annual Meeting for the following purposes, as more fully described in the accompanying proxy statement: 1. To elect the Board of Directors’ four nominees for director named herein to hold office until the 2027 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal. 2. To approve, on an advisory basis, the compensation of the Company’s named executive officers. 3. To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for our fiscal year ending December 31, 2024. 4. To conduct any other business properly brought before the meeting. These items of business are more fully described in the Proxy Statement accompanying this Notice. The record date for the Annual Meeting is April 1, 2024. Only stockholders of record at the close of business on that date may vote at the Annual Meeting or any adjournment thereo